key: cord-0914829-wewaoja6
authors: Kurtovic, Liriye; Beeson, James G.
title: Complement factors in COVID-19 therapeutics and vaccines
date: 2020-12-13
journal: Trends Immunol
DOI: 10.1016/j.it.2020.12.002
sha: c79f6e4a02bf468071b333d9b7432f188578601b
doc_id: 914829
cord_uid: wewaoja6

Complement is integral to a healthy functioning immune system and orchestrates various innate and adaptive responses against viruses and other pathogens. Despite its importance, the potential beneficial role of complement in immunity to SARS-CoV-2 has been overshadowed by reports of extensive complement activation in severe COVID-19 patients. Here, we hypothesize that complement may also have a protective role and could function to enhance virus neutralization by antibodies, promote virus phagocytosis by immune cells, and lysis of virus. These functions might be exploited in the development of effective therapeutics and vaccines against SARS-CoV-2.

deposition of complement proteins MASP2 (MBL pathway), C3, C4 and C5b-C9 has also been reported in lung and cutaneous tissue samples from severe COVID-19 patients, but healthy samples were included as experimental controls in only one single study (control data were not shown) [17] [18] [19] [20] . Moreover, complement may contribute to dysregulated cytokine responses observed in some COVID-19 patients, which has been described as a "cytokine storm", although there is some question as to whether this term is misleading given that the concentrations of IL-6 in COVID-19 patients have been reported to be up to 40-fold lower than what has been typically reported for acute respiratory distress syndrome (ARDS) [21] .

Therefore, this question needs to be further addressed; additional discussions on immune responses during COVID-19 have been reviewed elsewhere, to name a few [22, 23] .

There has been little investigation into the relationship between complement and clinical complications associated with SARS-CoV-2 infection. One study found moderate correlations between sC5b-C9 concentrations and a single marker of endothelial perturbation (von Willebrand factor, Spearman's correlation coefficient 0.517, p<0.001) [24] ; additional markers were quantified but their correlations were not reported [24] . In hospitalized patients, increased plasma concentration of sC5b-C9 was also associated with an increased odds of respiratory failure (odds ratio 31.9, confidence interval 1.3 to 746.6, p=0.03) relative to those with lower concentrations [25] . In critically-ill patients, the concentrations of MBL were correlated with markers of coagulopathy (D-dimer, Spearman's correlation coefficient 0.390, p=0.002) [26] . One study evaluated the relationship between complement and mortality and found that increased C3 in serum was associated with a reduced odds of mortality (odds ratio 0.073, confidence interval 0.007 to 0.722, p=0.025) relative to those with lower concentrations [27] .

Hypothetically, local and systemic complement activation during the acute phase of infection, prior to the development of adaptive immunity, may cause disease pathology. Potential mechanisms for complement-mediated pathology may include complement-induced inflammation, leukocyte infiltration, and MAC formation and lysis of virus-infected cells in the lung. While reasonable, the evidence to support the directionality of this hypothesis is scarce and inferring causality from case-control studies is often problematic, potentially leading to misleading conclusions. For example, neutralizing antibody titers against SARS-CoV-2 can increase with disease severity, yet neutralizing antibodies are also thought to contribute to protective immunity [28] . These differences, however, warrant further investigation. Many of the correlations reported have been from univariate analysis that did J o u r n a l P r e -p r o o f Journal Pre-proof not adjust for other co-variables that may have been associated with poor clinical outcomes [24] [25] [26] . There is also a lack of in vitro evidence to support the role of complement in disease pathology. Studies have shown that recombinant SARS-CoV-2 proteins can activate the MBL and alternative pathways, suggesting these mechanisms may contribute to disease pathology, although this remains to be rigorously assessed [29, 30] . Indeed, there is currently no direct evidence that complement can lyse SARS-CoV-2 infected human cells.

We instead highlight the possibility that complement might also play a protective role against SARS-CoV-2 infection. Patients with mild disease generally report normal serum concentrations of complement proteins (C3 and C4), which suggests that normally functioning immune mediators may be able to contribute to immunity and reduce disease severity [14] [15] [16] . In line with this, an examination of more than 6,000 COVID-19 patients found that individuals with a dysregulated complement system were more prone to developing severe disease than those with a healthy immune system [31] . Therefore, for most individuals, complement activation might contribute to reduced disease severity, whereas for a smaller percentage of individuals, complement might be dysregulated and associated with susceptibility to severe disease. This possibility remains to be tested.

Complement mediates protective immunity against many pathogens through activation of the antibody-dependent classical pathway. Currently, little is known about the potential role of antibody-complement interactions in immunity against SARS-CoV-2.

In some studies, innate complement activation and inflammation have also been implicated in the pathology of severe acute respiratory syndrome (SARS)[32-36], caused by SARS-CoV-1, and closely related to SARS-CoV-2. This might occur through MBL binding to the virus, which appears to be neutralizing, but could also lead to complement activation and Journal Pre-proof complement may act more potently against a human-specific pathogen than human complement would; indeed, enhanced cross-species activity was observed in a study of human complement against the murine-specific pathogen, Plasmodium berghei [38] .

Complement can also be activated by antigen-specific antibodies and therefore, can contribute to adaptive immune responses. Immunity to many viral and non-viral pathogens relies on antibodies and antibody-mediated neutralization. The binding of C1q alone or additional complement components can significantly enhance antibody neutralization, and in some cases, complement is essential for neutralizing activity. This has been demonstrated in vitro for the human pathogens, West Nile virus [6] [8, 42] , often using a combination of human and non-human (mouse, rabbit, guinea pig) antibodies and complement.

There appears to be some balance between the pathogenic and protective roles of complement observed with various infectious pathogens. For example, severe malaria is associated with innate complement activation and inflammation[43], while protective antimalarial immunity is associated with classical complement activation via antibodies [7, 44, 45 ]. Therefore, we hypothesize that under optimal conditions, antibodies and complement might contribute to pathogen neutralization and reduced disease severity. However, when the immune response is suboptimal and cannot effectively clear the infection, complement might instead become hyperactive and cause inflammation-related pathologies. This might also be true for SARS-CoV-2, whereby failure to control infection might lead to a high viral load that triggers multiple pathogenic processes, including those mediated by complement. This concept was supported by a repeat infection study in rabbits. Specifically, rabbits acquired some immunity after primary infection with MERS-CoV, but this was not sufficient to confer protection against re-infection, which instead resulted in increased inflammation. It was only after two infections that an appropriate antibody response was acquired, and when infected for a third time, the infection was controlled, and little immunopathology was observed [46] .

Altogether, complement has demonstrated both pathogenic and protective roles in immunity to various pathogens. 56, 57] . Few control studies have been performed; one of these evaluated a combination of C5 (eculizumab) and JAK1/2 (ruxolitinib) inhibitors (treatment n=7, control n=10)in COVID-19 patients [58] . A larger study evaluated the experimental treatment of severe patients with a C5-inhibitor (eculizumab; treatment n=35, control n=45) [59] . The treatment group presented enhanced survival at day 28 (p=0.005), although serious adverse events were 2-fold higher than in controls, and included infectious complications and ventilator-associated pneumonia [59] . The one randomized control, phase 2 trial (NCT04333420) i of a C5-inhibitor administered to severe COVID-19 patients (vilobelimab; treatment n=15, control n=15) found no improvement in the primary outcome of respiratory function (PaO 2 /FiO 2 ) [60] , but the authors noted that the study was not sufficiently powered to detect significant differences between groups [60] .

While these studies suggest some promise, it is too early to conclude whether complement inhibitors have any clinical benefit in treating severe COVID-19. Several clinical trials of AMY-101 and eculizumab are ongoing, as well as larger clinical studies. We also need to acknowledge that complement inhibitors may not be suitable for all patients, particularly for those with mild disease that display serum concentrations of complement proteins within the normal range [14] [15] [16] . Complement may contribute to mounting an effective immune response, and so, administration of therapeutics to inhibit complement might potentially be harmful in COVID-19 patients with mild disease who may be mounting an effective immune response. Furthermore, complement deficiencies are known to increase the risk of bacterial infections [61] , and several participants treated with eculizumab were reported to have bacterial infections and ventilator-associated pneumonia (some of which did not recover)[50, J o u r n a l P r e -p r o o f Journal Pre-proof neutralize SARS-CoV-2 in vitro [67, 68] . One of these MAbs (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) was also shown to reduce viral RNA copy numbers in a golden Syrian hamster model of SARS-CoV-2, compared to control animals that received saline solution only [68] . These MAbs have significant potential as candidate therapeutic and preventive agents. In general, recent advances in MAb technologies have identified a point mutation in the Fc region (E430G) of IgG that promotes hexamer formation between neighboring IgG molecules, significantly enhancing C1q binding and complement activation [69] . These hexamer antibodies have been largely explored in cancer therapeutics and demonstrate potent complement activation and complement-mediated lysis of cancer cells (isolated from patient cancer cells and cell-lines) in vitro [70] . These approaches might also be potentially valuable for treating infectious diseases, including COVID-19, which certainly merits further investigation. This principle was recently shown with Neisseria gonorrhoeae bacterial infection, whereby a MAb with the hexamerization mutation had greater complement fixation and protective efficacy than the wild-type IgG in a mouse infection model (wild-type BALB/c mice) [71] . Presumably, further enhancing the neutralizing activity of anti-SARS-CoV-2 MAbs by complement binding might be preferable to directly neutralizing MAbs that lack complement activity. We also propose considering combining different therapeutic approaches; for example, it might be possible to use engineered MAbs with enhanced C1q binding for viral neutralization in combination with a C5-inhibitor to prevent terminal complement activation and inflammation in specific clinical syndromes, such as ARDS. However, this remains to be tested.

From another angle, vaccines can also be modified to induce antibodies with enhanced binding to C1q; one approach is to modulate the IgG subclass profile, which can be achieved using appropriate vaccine adjuvants (E.g. QS21, AS01, MF59 and Alum) [72] . In humans, IgG1 and IgG3 can potently activate complement (IgG3>IgG1), while IgG2 and IgG4 have little to no activity [66] . Epitopes included in vaccine constructs are also important, as antibodies to different epitopes, even of the same antigen, can have considerable differences in the ability to bind C1q [73] . There is also evidence that targeting multiple epitopes might enhance antibody-complement activity overall [45] . However, little is currently known on whether these MAbs can bind C1q and activate complement, which might enhance neutralizing activity, even for those otherwise considered non-neutralizing antibodies.

The binding affinity of SARS-CoV-2 S protein to the receptor ACE2 is ~4-fold higher than seen for the closely related SARS virus, raising concerns that achieving highly effective neutralizing antibodies might be challenging with SARS-CoV-2[67]. We argue that J o u r n a l P r e -p r o o f Journal Pre-proof complement fixation by antibodies is worth exploring as a potential strategy to achieve maximal antibody-mediated virus neutralization. The molecular details of antibodies targeting SARS-CoV-2 are beginning to emerge, which can help understand the potential of complement interactions to enhance immunity. Neutralizing MAbs largely target the RBD and sterically block ACE2 receptor binding [74] . Therefore, C1q binding by antibodies might enhance inhibition of receptor binding. In contrast, non-neutralizing MAbs tend to bind outside the RBD [74] . Moreover, antibodies targeting specific epitopes have the potential for inter-molecular cross-linking of SARS-CoV2 S proteins, that might increase the effective avidity of IgG and increase antibody-mediated virus neutralization [75] . C1q binding to multiple IgG molecules might achieve a similar effect to increase the effective avidity and enhance neutralization. Collectively, further evaluations of the role of complement and how this cascade might enhance antibody activity might be a promising avenue to maximize the efficacy of antibody-based therapeutics and vaccines, awaiting future research.

Complement has multiple roles in immunity, including in innate and adaptive responses.

While excess complement activation has been implicated in severe COVID-19 disease pathology, data supporting this role, or the benefit of complement inhibitors, remain limited (see outstanding questions). Importantly, the potential involvement of complement factors in protective immunity has been largely ignored for SARS-CoV-2, but has been defined with other viruses, bacteria, and protozoa. Results from small studies of complement inhibitor therapeutics should not overshadow the potential to harness the beneficial activities of complement. The implications for antibody-complement interactions in virus neutralization and immunity need to be investigated and could be applied to antibody-based therapeutics or active vaccination strategies against SARS-CoV-2. 

Mild patients (n=32); severe patients (n=39).  in severe vs. mild (p<0.001). [76] MBL Patients (n=65); healthy controls (n=72).  in patients vs. controls (p=0.018).

[26]

Patients with respiratory failure (n=23) and without respiratory failure (n=16).

No difference between groups.

[25]

 What is the role of antibodies against SARS-CoV-2 in fixing and activating complement to mediate immunological functions, including enhanced virus neutralization and complement-mediated phagocytosis and lysis of the virus?

 What are the specific epitopes of antibodies that can potently bind and activate complement? Does targeting multiple epitopes by antibodies achieve greater complement fixation and activation?

 Can C1q binding by antibodies enhance SARS-CoV2 virus neutralization, as seen for some other viruses and pathogens? Does C1q binding increase receptor blocking effects of antibodies, or can C1q cross-link IgG to increase its effective avidity?

 What properties and mutations in monoclonal antibodies promote complement interactions and can these be exploited to increase therapeutic or prophylactic efficacy?

 Which vaccine designs, adjuvants, and constructs can effectively induce antibodies that fix and activate complement against SARS-CoV-2?

 What role do antibody-complement interactions play in naturally-acquired and vaccine-induced protective immunity against SARS-CoV-2?

 What is the role of innate complement activation in immunity to SARS-CoV-2? Does it play a role in controlling viremia?

 What are the specific mechanisms by which complement contributes to the pathogenesis of severe disease?

 Can inhibitors of complement activation be used therapeutically to reduce progression to severe disease, or improve outcomes in severe disease? What are the COVID-19 syndromes or complications for which complement inhibitors have the most clinical benefit?

J o u r n a l P r e -p r o o f

Overall, larger, randomized controlled clinical trials are required to formally REFERENCES

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Complement system part I -molecular mechanisms of activation and regulation

Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity

Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)

Membrane attack by complement: the assembly and biology of terminal complement complexes

Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus

Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against Malaria

Complement and its role in protection and pathogenesis of flavivirus infections

Contribution of acute-phase reaction proteins to the diagnosis and treatment of 2019 novel coronavirus disease (COVID-19)

Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

Distinguishable Immunologic Characteristics of COVID-19

Patients with Comorbid Type 2 Diabetes Compared with Nondiabetic Individuals

Diarrhea is associated with prolonged symptoms and viral carriage in COVID-19

Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases

Vascular obliteration because of endothelial and myointimal growth in COVID-19 patients

Investigating the spectrum of dermatologic manifestations in COVID-19 infection in severely ill patients: A series of four cases

Docked severe acute respiratory syndrome coronavirus 2 proteins within the cutaneous and subcutaneous microvasculature and their role in the pathogenesis of severe coronavirus disease

Is a "cytokine storm" relevant to COVID-19?

Immunity, endothelial injury and complement-induced coagulopathy in COVID-19

SARS-CoV-2 and coagulation disorders in different organs

Mild clinical course of COVID-19 in 3 patients receiving therapeutic monoclonal antibodies targeting C5 complement for hematologic disorders

Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience

Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19

Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19

Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study

Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Complement deficiency states and associated infections

Correlates of protection induced by vaccination

Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19

Active human complement reduces the Zika virus load via formation of the membrane-attack complex

Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Complement is activated by IgG hexamers assembled at the cell surface

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering

Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody

Adjuvants: classification, modus operandi, and licensing

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20

Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies

Clinical Characteristics and Immune Injury Mechanisms in 71 Patients with COVID-19

Abnormal immunity of non-survivors with COVID-19: predictors for mortality

Neutrophils and Contact Activation of Coagulation as Potential Drivers of COVID-19

C3 Patients (n=33)

Some  (9.7%) than normal range

Patients (n=30)

Some  (47%) that normal range

Patients (n=182)

Some  (12%) or  (19%) s than the normal range

Patients (n=72); healthy controls (n=20)

Patient survivors (n=169) and non-survivors (n=67)

 in non-survivors vs. survivors (p<0.05)

C3a Patients (n=122); healthy controls (n=10)

Patients receiving maintenance hemodialysis (n=39); hemodialysis controls (n=10)

C3c Patients (n=122); healthy controls (n=10)

C4 Patients (n=33)

Some  (12.9%) or  (3.2%) than normal range

Within the normal range

Patients (n=182)

Some  (4%) or  (4%) s than the normal range

Patients (n=72); healthy controls (n=20)

 in non-survivors vs. survivors (p=0.001); within normal range for the survivor group

C4d Patients with respiratory failure (n=23) and without  in patients with respiratory failure

C5a Patients (n=148)

Patients (n=17); healthy controls (n=27)

Mild patients (n=54); moderate patients (n=68)

severe patients (n=106)

 with disease severity (p=0.02)

Patients with respiratory failure (n=23) and without respiratory failure (n=16). No difference between groups

Patients (n=122); healthy controls (n=10)

Patients (n=17); healthy controls (n=27)

Patients (n=25); healthy controls (n=10)

The authors were supported by funding from the National Health and Medical Research Council of Australia (grants 1173046, 1092789). Burnet Institute is supported by the